ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
EudraCT number 2010-021961-61
Protocol number VOS-AML-301
Sponsor Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard, Suite 400, South San Francisco CA 94080 USA
Indications Hemato-oncology
Diagnosis Acute myeloid leukemia
Population in clinical trial Adults (18-65 years)
Year of receiving the request to Institute (SÚKL) 2010
Date of approval by Institute (SÚKL) 27.2.2011
Date of approval by EC 16.2.2011
Date of initiation CT in ČR 20.1.2012
Date of ending CT in ČR 22.6.2015
Sites Odd. klinické hematologie, FN Královské Vinohrady, Šrobárova 50 Praha 10 100 34 (discontinued)
Odd. klinické hematologie, FN Hradec Králové, Sokolská 581 500 05 Hradec Králové (discontinued)
Hematoonkologická klinika, FN Brno, Jihlavská 20 625 00

‹‹ Back to list